Previous 10 | Next 10 |
home / stock / medxf / medxf news
TORONTO and CHICAGO, March 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 35th Annual Roth Conference from March 12 to 14, 2023. Event : 35th Annual Roth Confer...
Medexus Pharmaceuticals Inc Q3 2023 Results Conference Call February 09, 2023 08:00 AM ET Company Participants Victoria Rutherford - Investor Relations Ken d’Entremont - Chief Executive Officer Marcel Konrad - Chief Financial Officer Conference Call Partic...
Results reflect growth across all leading prescription products, demonstrating continued track record of strong overall performance Management to host conference call at 8:00 AM Eastern Time on Thursday, February 9, 2023 TORONTO and CHICAGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Medexus...
Harmony P. Garges MD MPH and Menassie Taddese MBA appointed to Medexus’s board of directors Appointments bolster Medexus board’s medical and financial expertise, particularly in the United States TORONTO and CHICAGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -...
TORONTO and CHICAGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government-sponsored coverage of Cuvposa (glycopyrro...
TORONTO and CHICAGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 9, 2023 to discuss Medexus’s results for its third fiscal quart...
Medexus Pharmaceuticals ( OTCQX:MEDXF ) said it expects it will take its German partner medac up to a year or more to collect and submit the information requested by the U.S. Food and Drug Administration (FDA) for their therapy treosulfan. Medac had resubmitted a new drug app...
Medexus Pharmaceuticals ( OTCQX:MEDXF ) ( TSX: MDP:CA ) said its FQ3 revenue is expected to be between $28.5M and $29.0M, an increase of 34% Y/Y and at least 3% Q/Q. The company said the primary drivers for the revenue increase were increases in net sales across the company's port...
TORONTO and CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended December 31, 2022 (the company’s fiscal ...
Medexus Pharmaceuticals Inc. (MEDXF) Q2 2023 Earnings Conference Call November 9, 2022 08:00 ET Company Participants Victoria Rutherford - Investor Relations, Adelaide Capital Ken d’Entremont - Chief Executive Officer Marcel Konrad - Chief Financial Office...
News, Short Squeeze, Breakout and More Instantly...
Medexus Pharmaceuticals Inc Company Name:
MEDXF Stock Symbol:
OTCMKTS Market:
Medexus Pharmaceuticals Inc Website:
FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended Mar...
2024-06-06 12:08:44 ET In the United States, a new drug application, or NDA, is the vehicle through which drug sponsors formally propose that the FDA approve a new %Pharmaceutical for sale and marketing. And news that the FDA has accepted this firm’s resubmission is sending share...